This research marked the discovery of mortaparib as the first dual inhibitor of mortalin and PARP-1, exhibiting its molecular mechanism of action and demonstrating in vitro and in vivo tumor suppressor activity, ultimately emphasizing its potential as an anticancer drug (Putri et al., 2019). The gene discussed is HSPA9; the disease is neoplasm.